Association between gut microbial dysbiosis and clinical prognosis of advanced colorectal cancer

Table 1 Comparison of clinicopathological and treatment-related data of patients with advanced colorectal cancer between the two groups, median (interquartile range)/n(%)

Variable	Normal flora group (n = 48)	Abnormal flora group (n = 76)	Z/χ2	P value
Demographic characteristics
Male	27 (56.25)	45 (59.21)	0.106	0.745
Age (years)	63.5 (54.25, 71.75)	60.00 (53.00, 72.00)	0.703	0.482
BMI (kg/m2)	22.82 (21.34, 26.02)	22.82 (19.87, 25.51)	0.972	0.331
Smoking history	15 (31.25)	26 (34.21)	0.117	0.733
Drinking history	13 (27.08)	24 (31.58)	0.284	0.594
Hypertension	14 (29.17)	24 (31.58)	0.081	0.777
Type 2 diabetes mellitus	7 (14.58)	15 (19.74)	0.535	0.464
Tumor pathological characteristics
Primary tumor site			0.041	0.905
Colon	26 (54.17)	42 (55.26)
Rectum	22 (45.83)	34 (44.74)
Maximum tumor diameter (cm)	4.65 (4.06, 6.14)	4.92 (3.79, 5.87)	0.693	0.489
Histological differentiation			11.297	0.001
Well/moderate differentiation	39 (81.25)	39 (51.32)
Poor differentiation	9 (18.75)	37 (48.68)
TNM staging			10.728	0.001
IIIB-IIIC	37 (77.08)	36 (47.37)
IV	11 (22.92)	40 (52.63)
Positive vascular invasion	15 (31.25)	44 (57.89)	8.374	0.004
Positive perineural invasion	13 (27.08)	39 (51.32)	7.095	0.008
Elevated preoperative CEA	28 (58.33)	50 (65.79)	0.701	0.402
Elevated preoperative CA19-9	25 (52.08)	44 (57.89)	0.403	0.526
Treatment regimen			0.043	0.979
Radical resection + adjuvant chemotherapy	23 (47.92)	35 (46.05)
Palliative chemotherapy	16 (33.33)	26 (34.21)
Chemotherapy combined with targeted therapy	9 (18.75)	15 (19.74)

BMI: Body mass index; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.